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High throughput formulation screening:  
Testing a novel two compartment microtiter plate approach
Ann-Christin Jacobsen1, Martin Brandl1, Annette Bauer-Brandl1
1Drug Transport & Delivery Group, Department of Physics, Chemistry & Pharmacy,  
University of Southern Denmark, Odense Denmark
PURPOSE
A novel two compartment microtiter plate-based high throughput formulation 
screening (HTFS) approach was tested for its suitability for formulation 
performance ranking of enabling formulations.  
Many new drug compounds have poor solubility and require complex 
formulation to enable oral administration. Identification of the optimum 
formulation design/composition can be a challenging and costly process, which 
may be bypassed by the present approach. 
CONCLUSIONS
The two compartment 
microtiter plate approach 
was generally able to predict 
the formulation performance 
in vivo. 
Varying the screening 
parameters of the HTFS 
approach indicated that the 
protocol can be simplified to 
achieve high practicability 
and simultaneously high 
predictability. 
FUTURE OUTLOOK
Testing the novel approach with 
other formulations of poorly 
soluble drug compounds will 
reveal it’s usefulness in early 
drug development.  
RESULTS 
OBJECTIVES
The HTFS approach was tested using model formulations of tadalafil (TDF) 
with/without the amphiphilic polymer Soluplus® (crystalline and amorphous 
formulations). Formulations were evaluated with respect to both the amount of drug 
dissolved and the amount of drug permeated. 
• Can the HTFS approach predict the formulation performance in vivo? 
 The in vitro HTFS results were compared to in vivo data from literature.
• How do screening parameters affect HTFS practicability and predictability?
 The following test parameters were evaluated: 
1) Incubation time, 2) acceptor media and 3) dispersion (i.e. donor) media 
REFERENCES / ACKNOWLEDGEMENTS
CONTACT INFORMATION: annette.bauer@sdu.dk
W1130-02-
014
TDF concentration in acceptor
In vitro in vivo correlation: Comparing the HTFS results to in vivo data from Krupa et al. 2016
METHODS
Figure 2 shows a flow diagram of the HTFS protocol used in 
all experiments.  
• Four TDF formulations (i.e. suspensions) were prepared:
1) Crystalline TDF, 2) Crystalline TDF and Soluplus® (physical mixture), 
3) freeze dried TDF and 4) ‘co’-freeze dried TDF and Soluplus® (solid 
dispersion).
• Three dispersion media were used for the suspensions: 
1) 50 mM phosphate buffer, 2) Simulated gastric fluid (SGF) and 
3) Fasted state simulated intestinal fluid (FaSSIF).
• Five acceptor media containing surfactants were 
evaluated and compared to neat medium: 
1) 1% Sodium dodecyl sulfate (SDS), 2) 0.2% d-α-Tocopheryl polyethylene
glycol 1000 (VitE TPGS), 3) 1% VitE TPGS, 
4) 0.2% Polysorbate 80 (PS 80) and 5) 1% PS 80. 
300 µL suspension and 200 µL acceptor medium were 
transferred to the bottom-wells and top-wells, respectively,  
and incubated for 1, 3 or 6h. Figure 1 shows the assembled 
system. TDF concentration was determined via UHPLC.
Top-well
Bottom-wellDialysis membrane
Figure 1 The two compartment 96-well microtiter plate.
Figure 2 Flow diagram of the HTFS protocol.
Incubation for 6 
h enables  
Influence of screening parameters
Figure 3 TDF concentration in A) the donor compartment (dissolved) or B) the 
acceptor compartment (permeated) vs in vivo AUC.
Figure 4 TDF concentration in the acceptor after 6h of 
incubation using differ nt cceptor media. The dotted line 
indicates the TDF concentration when using neat buffer. 
Dispersion 
medium
R² (dissolved 
concentration 
vs AUC)
R² (permeated 
concentration  
vs AUC)
Phosphate 
buffer
0.8459 0.8499
SGF 0.826 0.8637
FaSSIF 0.8282 0.9391
Table 1 Coefficients of determination (R²) when 
plotting the TDF concentration in either the donor 
compartment (dissolved TDF) or the acceptor 
compartment (permeated TDF) versus the 
in vivo AUC (Krupa et al. 2016). Incubation time: 
6h, Acceptor medium: 1% VitE TPGS 
A) B)
Dispersion media 
Acceptor media 
Using surfactant solutions 
as acceptor medium 
increased TDF permeation 
as compared to neat buffer: 
Sink conditions
No difference between 
surfactants.
Figure 5 TDF concentration in the acceptor compartment 
after 1, 3 and 6h of incubation. Acceptor medium: 1% VitE
TPGS. 
Incubation time
Steady TDF 
transport over the 
dialysis membrane 
for at least 6h. 
Longer incubation 
increased analytical 
ease.
FaSSIF as dispersion medium 
yielded the highest TDF 
concentration in the 
donor compartment followed 
by SGF and phosphate buffer.
The same clear difference in 
TDF concentration could not 
be seen in the acceptor 
compartment.  
Figure 6 TDF 
concentration in 
A) the donor 
compartment or 
B) the acceptor 
compartment 
after 6 h of 
incubation using 
different media 
for dispersion of 
the formulations. 
Acceptor 
medium: 
1% VitE TPGS
A) B)
A good in vitro in vivo 
correlation was achieved.
TDF concentration in the 
acceptor compartment 
(permeated TDF) generally 
yielded a better prediction 
at same time providing 
experimental ease 
(no separation step).
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